2023-01-26 01:08:00

Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue in 11 countries, only 1 year after approval in...

Logo PR Newswire
PR Newswire

"Expected to change GERD drug market landscape"

  • Application for product approval of Fexuclue, a new drug for gastroesophageal reflux disease (GERD), has been completely submitted to Colombia, Vietnam, and Saudi Arabia
  • NDA submissions in 11 countries completed in the shortest time among K-pharma new drugs... accelerating expansions into $1.61 billion market

SEOUL, South Korea, Jan. 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical's Fexuclue (active ingredient: Fexuprazan) is attracting attention as a game changer in the global gastroesophageal reflux disease (GERD) treatment market as it applied for approval in 11 countries across the world within one year after approval in Korea.

The company said on the 25th that it recently submitted a new drug application (NDA) for Fexuclue, a GERD drug, in Saudi Arabia. With this application, Daewoong completed NDA applications in 11 countries around the world in one year after securing permission for Fexuclue in Korea.

According to the 2021 data of IQVIA Global MIDAS, a pharmaceutical market research firm, the cumulative anti-ulcer drug market in 11 countries where Daewoong Pharmaceutical has submitted product approvals is estimated to be worth $1.61 billion (2 trillion won). The 11 countries in which the company has thus far submitted applications for Fexuclue approval include Brazil, the Philippines, Indonesia, Thailand, Mexico, Chile, Ecuador, Peru, Colombia, Vietnam, and Saudi Arabia.

Daewoong has also completed the submission of NDA for all four Latin American countries (Colombia, Ecuador, Peru, and Chile) that signed out-license agreements in 2021, and submitted an NDA to Vietnam to further accelerate its advance into the Asian market.

Based on the recent achievement to make a partnership with 15 countries, the company plans to further accelerate its global expansion for the growth of its blockbuster new drug. First of all, it plans to apply for product approval in 30 countries across the world by 2025 and launch in 100 countries by 2030. In particular, it won product approval in the Philippines in November last year for the first time in the world, and this year it will submit an application for product approval to advance into China, which has grown into the world's largest anti-ulcer drug market beyond the United States with a market size of $3.53 billion (4.37 trillion won) as of 2021.

Fexuclue Tablet is a new drug for GERD officially launched by Daewoong Pharmaceutical in Korea in July last year and is a potassium-competitive acid blocker (P-CAB) drug. By improving the drawbacks of existing proton pump inhibitors (PPIs), it binds to the proton pump without activating gastric acid and quickly and stably inhibits the secretion of gastric acid. There are two indications it has secured so far: treatment of erosive GERD (40 mg) and improvement of gastric mucosal lesions in acute and chronic gastritis (10 mg). In particular, Fexuclue is the only P-CAB drug for gastritis indications in Korea. The compound patent expires approximately in 2036, with extension potential.

Seng-ho Jeon, CEO of Daewoong Pharmaceutical, said, "The fact that Fexuclue completed applications for approval in the most countries in such a short period of time after approval among new drugs developed in Korea proves our cumulative know-how and ability to develop global new blockbuster drugs. Along with the sequential expansion of overseas approval and launch, we will accelerate not only the expansion of indications through the promotion of multifaceted clinical trials but also but also diversify formulation to improve the value of product."

Daewoong Pharmaceutical is conducting phase 3 clinical trials for additional indications for maintenance therapy after treatment of erosive GERD and prevention of ulcers caused by non-steroidal anti-inflammatory drugs (NSAIDs), and also commenced on clinical trials for eradicating Helicobacter pylori. In addition, it is preparing to expand its lineup through the development of orally disintegrating tablets and IV formulations (injections) for patient convenience.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/daewoong-pharmaceutical-submitted-nda-for-its-global-new-drug-fexuclue-in-11-countries-only-1-year-after-approval-in-korea-301731095.html

SOURCE Daewoong Pharmaceutical Co., Ltd.

HealthBy Katherine Ellen Foley2023-03-29 13:31:59
The FDA on Wednesday approved Narcan, an opioid overdose reversal drug, to be sold without a prescription. The approval marks the first time any form of...

Logo EIN Presswire
HealthPress Release2023-03-29 06:53:29
Osteoarthritis Therapeutics PORTLAND, OR, UNITED STATES, March 29, 2023 / EINPresswire.com / -- The Osteoarthritis therapeutics market refers to the industry...

Logo PR Newswire
HealthPress Release2023-03-29 17:03:00
Product sales in China for 2022 increased 50% compared to the same period in 2021, while product development and commercialization are steadily advancing....

Logo PR Newswire
HealthPress Release2023-03-29 00:00:00
Building an Innovative Biopharmaceutical Company with Sustainable Growth and Comprehensive Capability ROCKVILLE, Md. and SUZHOU, China, March 29, 2023...

Logo U.S. News & World Report
PoliticsBy Associated Press2023-03-29 12:52:31
The U.S. Food and Drug Administration on Wednesday approved selling naloxone without a prescription, setting the overdose-reversing drug on course to become...

Logo PR Newswire
HealthPress Release2023-03-29 06:06:00
SHANGHAI, March 29, 2023 /PRNewswire/ -- On March 27, 2023, the release date of its 2022 Annual Report, Fosun Pharma (stock code: 600196.SH; 02196.HK) also...

Logo PR Newswire
HealthPress Release2023-03-29 14:00:00
-The joint research will use bitBiome's drug discovery platform technology to search for drug candidate substances- TOKYO, March 29, 2023 /PRNewswire/ --...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-03-29 00:02:00
- Accu-ChekGuide Me glucose meter to be paired with BlueStar in Japan, which is being jointly developed by Astellas and Welldoc - - Initiation of clinical...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-03-29 17:30:00
Lupus A ccelerating B reakthroughs C onsortium to address challenges impacting lupus trial success and to accelerate treatment breakthroughs WASHINGTON,...

Logo Benzinga
Business / FinanceBy Globe Newswire2023-03-29 13:48:20
NARCAN Naloxone HCl Nasal Spray 4 mg is currently the first and only prescription strength naloxone nasal spray to receive over-the-counter status in the...

Logo PR Newswire
HealthPress Release2023-03-28 08:20:00
Performance Highlights: During the reporting period, the revenue was RMB 43. 952 billion, with a year-on-year growth of 12.66%; the net profit after...

Logo EIN Presswire
HealthPress Release2023-03-29 14:49:31
The Insight Partner Logo The Future of Herbal Supplements: Key Growth Drivers and Emerging Trends NEW YORK, NEW YORK, USA, March 29, 2023 / EINPresswire.com...

Logo EIN Presswire
HealthPress Release2023-03-29 14:39:30
Brain Health Supplements Market1 PORTLAND, OR, UNITED STATE, March 29, 2023 / EINPresswire.com / -- Brain Health Supplements Market - Global Outlook and...

Logo EIN Presswire
HealthPress Release2023-03-29 12:43:20
x ray Global Ulcerative Colitis Treatment Market Manufacturers, Growth Rate and Market Situation Analysis 2023-2033 NEW YORK, NY, UNITED STATES, March 29,...

Logo PR Newswire
HealthPress Release2023-03-28 18:07:00
READING, Pa., March 28, 2023 /PRNewswire/ -- PharmaForce International (PFI) recently published a report in December that benchmarked the leading Immunology...

Logo PR Newswire
HealthPress Release2023-03-29 05:27:00
SUZHOU, China, March 29, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with...

Logo PR Newswire
HealthPress Release2023-03-29 14:00:00
The new solutions will support pharma manufacturers navigating new state requirements on drug reporting COLUMBUS, Ohio, March 29, 2023 /PRNewswire/ -- Today,...

Logo PR Newswire
HealthPress Release2023-03-29 17:23:00
SAN DIEGO, March 29, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of...

Logo Daily Mail
HealthBy Cassidy Morrison Senior2023-03-29 13:17:07
Narcan, the nasal spray that rapidly reverses opioid overdoses, can now be sold over the counter without a prescription, the Food and Drug Administration...

Logo GlobeNewswire
SciencePress Release2023-03-29 12:00:00
Phase 2b clinical trial for AB-2004 in autism irritability ongoing and enrollment anticipated to be complete by end of 2023 IND-enabling studies ongoing for...